Skip to main content

Table 2 Echocardiographic parameters at 8 weeks follow-up

From: Dapagliflozin attenuates diabetes-induced diastolic dysfunction and cardiac fibrosis by regulating SGK1 signaling

  Control Diabetes Diabetes+dapa
LAD, mm 8.8 ± 0.3 9.9 ± 0.4 9.4 ± 0.3
LVEDD, mm 14.4 ± 0.7 14.6 ± 0.7 14.3 ± 0.8
LVESD, mm 9.2 ± 0.6 9.3 ± 0.4 9.4 ± 0.3
IVSd, mm 3.6 ± 0.2 3.5 ± 0.3 3.6 ± 0.3
PWd, mm 3.2 ± 0.1 3.5 ± 0.3 3.7 ± 0.2
LVEF (%) 69 ± 2 72 ± 1 73 ± 1.6
LVFS (%) 36 ± 2 38 ± 1 39 ± 1.3
E, cm/s 61 ± 4 69 ± 10 67 ± 5.1
A, cm/s 34 ± 3 59 ± 7 45 ± 5.7
Septal e′, cm/s 9.6 ± 0.4 5.6 ± 0.7* 9.6 ± 0.6
Lateral e′, cm/s 13.2 ± 1.0 8.2 ± 1.9* 13.1 ± 0.5
E/septal e′ 6.6 ± 0.6 12.9 ± 1.6* 7.2 ± 0.6
  1. Values are means ± SEM (n = 10 per group)
  2. SGLT2i sodium-glucose cotransporter 2 inhibitor, LAD left atrial diameter, LVEDD left ventricular end-diastolic diameter, LVESD left ventricular end systolic diameter, IVSd interventricular septal end diastole thickness, PWd posterior wall thickness, end diastole, LVEF left ventricular ejection fraction, LVFS left ventricular fractional shortening
  3. *p < 0.05 compared to control group, p < 0.05 compared to diabetes group